---
title: IPALT
slug: ipalt
qid: 
snapshot: enwiki-001360364413
content_hash: 
license: CC BY-SA 4.0
source: https://en.wikipedia.org/w/index.php?oldid=1360364413
tags: [106462793, 106462794, 107077446, 108147884, 129309052, 23603337, 26220375, 27236659, 33905804, 37750075, 43371250, 50769796, 54374437, 63001193, 63007578, 65121944, 68150358, 73750206, 90256262, 90256265, 90318773, 90894244]
---

# IPALT

> [!note] Provenance
> Snapshot `enwiki-001360364413` · content root `…`
> Derived from <https://en.wikipedia.org/w/index.php?oldid=1360364413> · Licensed CC BY-SA 4.0

iPALT, or ALiPT, also known as N-isopropyl-N-allyltryptamine or by its developmental code name ASR-3003, is a serotonin receptor modulator of the tryptamine family. It is an asymmetrical analogue of diisopropyltryptamine (DiPT) and diallyltryptamine (DALT). The drug is a non-selective serotonin receptor agonist, including of the serotonin 5-HT 1B , 5-HT 2A , 5-HT 2B , and 5-HT 6 receptors, but not of the serotonin 5-HT 1A receptor. It is also a serotonin reuptake inhibitor, but does not inhibit dopamine or norepinephrine reuptake. The drug shows rather low potency for many of these actions, with for example 47-fold lower potency as a serotonin 5-HT 2A receptor agonist than the known psychedelic drug 5-MeO-iPALT (ASR-3001). The chemical synthesis of iPALT has been described. Derivatives of iPALT include 5-MeO-iPALT (ASR-3001), 4-HO-iPALT, and 2-Me-iPALT (ASR-3002). 5-MeO-iPALT is known to be a psychedelic drug in humans and is under development for potential medical use. iPALT was patented by the Alexander Shulgin Research Institute (ASRI) in 2024.

iPALT, or ALiPT, also known as N-isopropyl-N-allyltryptamine or by its developmental code name ASR-3003, is a serotonin receptor modulator of the tryptamine family. It is an asymmetrical analogue of diisopropyltryptamine (DiPT) and diallyltryptamine (DALT). The drug is a non-selective serotonin receptor agonist, including of the serotonin 5-HT 1B , 5-HT 2A , 5-HT 2B , and 5-HT 6 receptors, but not of the serotonin 5-HT 1A receptor. It is also a serotonin reuptake inhibitor, but does not inhibit dopamine or norepinephrine reuptake. The drug shows rather low potency for many of these actions, with for example 47-fold lower potency as a serotonin 5-HT 2A receptor agonist than the known psychedelic drug 5-MeO-iPALT (ASR-3001). The chemical synthesis of iPALT has been described. Derivatives of iPALT include 5-MeO-iPALT (ASR-3001), 4-HO-iPALT, and 2-Me-iPALT (ASR-3002). 5-MeO-iPALT is known to be a psychedelic drug in humans and is under development for potential medical use. iPALT was patented by the Alexander Shulgin Research Institute (ASRI) in 2024.
